Videos

Experts urge caution prescribing GLP-1s for patients with eating disorders, highlighting motivation checks, psychoeducation, and team-based care.

Safety data, not just efficacy, determines how comfortable clinicians feel prescribing. The panel reviews the safety profile, dosing schedule, and drug interactions relevant to a newer agitation therapy.

Pivotal trial data can reshape when clinicians feel comfortable starting treatment. The panel walks through the short- and long-term study results behind a newer agitation therapy in detail.

GLP-1 weight-loss drugs may aid binge eating, but clinicians must screen for eating disorders and monitor patients with multidisciplinary care.

Explore how TMS might be useful in treating schizophrenia, and how researchers are working to localize target areas.

Causal lesion and stimulation studies map psychosis to hippocampus–thalamus circuits, pointing to a reproducible TMS target for schizophrenia symptoms.

Adolescent synaptic pruning may fuel schizophrenia; researchers explore how restoring plasticity could ease fixed delusions.

Primate brain tissue studies track pruning, myelination, and dopamine across development, revealing adolescence-linked neural dynamics that may explain schizophrenia risk.

Learn how to launch TMS or Spravato services—costs, billing, REMS logistics, training, and what’s next in interventional psychiatry.

After 2 antidepressant trials, TMS or esketamine offers faster relief and durable remission—see why clinicians switch sooner.

See how telehealth, teach-back, and trusted community education boost health literacy and tackle social determinants.

Untreated ADHD carries measurable costs in relationships, careers, and even life expectancy. The panel makes the clinical case for diagnosing and treating adult ADHD as early as possible.

Being out of the hospital is not the same as being well. The panel makes the case for measurement-based care and more ambitious, individualized treatment goals for patients living with schizophrenia.

Many adults with ADHD are hiding in plain sight behind a prior anxiety or depression diagnosis. The panel examines underdiagnosis trends and how to identify ADHD beneath common comorbid conditions.

Negative and cognitive symptoms shape daily functioning far more than clinicians often recognize. The panel discusses building trust, using structured tools, and addressing tardive dyskinesia to close a persistent care gap.

An interventional cardiologist and psychiatrist share bedside clues and red flags for palpitations misdiagnosed as panic disorder.

Potential anti-anxiety agent SNTX-2643 blunted the brain's stress response for 24 hours, with no dissociative or abuse-related effects.

Real-world data highlights Lybalvi’s impact on acute care use in high-risk patients and Aristada’s long-acting dosing for steadier schizophrenia treatment.

Brenipatide being investigated for alcohol use disorder, while exploring relapse prevention in recurrent depression and other psychiatric conditions.

Phase 1 brenipatide shows week-long exposure and tolerable GI effects, fueling studies in alcohol and other substance use disorders.

New phase 3 data test PP-01 to ease cannabis withdrawal, pairing medication with behavioral therapy for moderate-to-severe cannabis use disorder.

Two on-label options are not enough for every patient. The panel weighs the field's remaining unmet needs against the biological rationale behind a newer, non-antipsychotic approach to treatment.

Decades of off-label prescribing for agitation associated with dementia due to Alzheimer’s are colliding with new evidence and new regulation. The panel examines why practice has lagged behind the data, and what is now changing.

A fast-tracked once-daily pill aims to ease cannabis withdrawal by restoring CB1 signaling and reward-pathway balance as phase 3 enrollment surges.

APSARD nears publishing adult ADHD guidelines. Here's what resources you can expect to see upon their publication.

APSARD's US Adult ADHD Guidelines have advanced to Stage 3, the last review phase before a targeted fall 2026 publication.

A detailed case study reveals how positive, negative, and cognitive symptoms can persist for years even when a patient appears clinically stable, challenging the panel to define what genuine functional recovery should look like.

Despite effective treatments, most patients with schizophrenia go undertreated. The panel examines how stigma, fear, and outdated expectations for recovery continue to limit both patients and the clinicians who treat them.

Explore how hormones, labs, and medical conditions reshape psychiatric care—practical ordering tips and red flags from a new clinician-focused podcast.

Psychiatrist Craig Katz, MD, shows how resilience-based trauma care reduces stigma, avoids PTSD overdiagnosis, and guides patients.